Daydrop® Triple Action for Allergic Eye Symptoms

Inclusion Criteria: * Adults aged 18 years or older * Active episode of allergic conjunctivitis prior to study initiation, assessed and confirmed by the specialist using a slit-lamp examination. * Score of ≥ 2 points on either the Ora Calibra Ocular Itching Score or the Ocular Redness Score, as assessed by the participant and the investigator, respectively. * Ability to self-administer the study product. * Ability to understand the Patient Information Sheet and provide written informed consent. Exclusion Criteria: * History of hypersensitivity to any component of the study product. * Systemic treatment with antihistamines (e.g., loratadine, cetirizine, desloratadine, ebastine) or corticosteroids (e.g., fluorometholone, loteprednol, dexamethasone), and/or topical treatment with any ophthalmic medication with anti-allergic or anti-inflammatory activity, including antihistamines or mast cell stabilizers (e.g., olopatadine, ketotifen, azelastine) and ophthalmic corticosteroids (e.g., fluorometholone, loteprednol, dexamethasone), except for artificial tears, within the week prior to study initiation. * Clinically significant ocular infection or inflammation. * Other active ocular conditions, including but not limited to glaucoma, Sjögren's syndrome, severe dry eye disease, Stevens-Johnson syndrome, active uveitis or keratitis, severe or chronic blepharitis, and other forms of conjunctivitis of non-allergic origin. * Ocular surgery within the 3 months prior to study entry. * Refractive surgery within the previous 6 months. * Pregnancy or planned breastfeeding.